The Advanced Prostate Cancer Consensus Conference (APCCC) focuses on areas where clinical evidence may be limited, conflicting or insufficient to support a clear treatment approach. The conference addresses the evolving management of locally advanced prostate cancer, biochemical recurrence and metastatic prostate cancer, while considering developments in imaging, biomarkers, molecular characterisation, genetics and emerging treatment strategies.

A central element of APCCC 2028 is its international expert consensus process. More than 100 specialists form the expert panel, contributing to predefined questions covering important areas of advanced prostate cancer management. Through presentations, debates, discussions and consensus voting, APCCC aims to summarise available evidence and provide expert perspectives on challenging areas of clinical decision-making.

The conference also supports knowledge exchange and international collaboration among prostate cancer specialists. Attendees have opportunities to engage directly with expert panellists and participate in discussions addressing contemporary issues in prostate cancer care. Following APCCC meetings, consensus recommendations are developed and published in the medical literature.

Whether you are a urologist, medical oncologist, radiation oncologist, researcher, cancer physician or other healthcare professional involved in prostate cancer care, APCCC 2028 offers an opportunity to explore emerging evidence, discuss complex clinical scenarios and engage with an international multidisciplinary community focused on improving the management of advanced prostate cancer.